Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Ru Cat. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN107954821A reveals ruthenium catalyzed synthesis for high-purity naphthalene derivatives offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN113636968B details a Ru-catalyzed transfer hydrogenation route for 3-acylpyrroles, offering high atom economy and simplified purification for API intermediates.
Novel ruthenium-catalyzed method enables high-purity 3-acylpyrrole production with enhanced supply chain reliability and significant cost reduction potential for pharmaceutical intermediates.
Novel ruthenium-catalyzed method achieves high-yield synthesis of trifluoromethyl dihydrobenzochromene with simplified process flow enabling cost-effective manufacturing and reliable supply chain for pharmaceutical intermediates.
Patent CN115286609B enables high-yield production of trifluoromethyl dihydrobenzochromene via ruthenium catalysis, offering cost reduction in pharmaceutical intermediate manufacturing and enhanced supply chain reliability.
Patent CN105732619A enables one-step synthesis of tetrahydropyridinopyrimidine intermediates with simplified process flow and enhanced supply chain reliability for pharmaceutical manufacturers.
Patent CN115286609B enables high-yield synthesis of fluorinated heterocycles with enhanced safety and scalability, offering significant cost reduction in pharmaceutical intermediate manufacturing.
This patent introduces a novel ruthenium-catalyzed alcohol-hydrogen transfer coupling method for synthesizing structurally diverse 3-acylpyrrole compounds with exceptional atom economy and simplified purification protocols enabling reliable supply chain solutions.
Patent CN115286609B enables high-yield production of trifluoromethyl dihydrobenzochromene with simplified process flow enhancing supply chain reliability and reducing manufacturing costs for pharmaceutical intermediates
Novel ruthenium-catalyzed method achieves >95% yield with scalable process for fluorinated heterocycles, enabling cost-effective production and reliable supply chain for pharmaceutical intermediates.
Ruthenium-catalyzed synthesis eliminates additives and oxidants, enabling sustainable scale-up for high-purity pharmaceutical intermediates and electronic materials supply chains.
Patent CN115286609B enables high-yield synthesis of trifluoromethyl dihydrobenzochromene intermediates with simplified process and enhanced supply chain reliability for global pharmaceutical manufacturers.
Patent CN115286609B enables high-yield synthesis of trifluoromethyl dihydrobenzochromene with simplified scalability and enhanced supply chain reliability for pharmaceutical manufacturing.
Patent CN109516998B details a novel synthesis method for Baloxavir intermediate with mild conditions and high chiral purity without resolution steps enabling significant cost savings and enhanced supply chain reliability.
Novel ruthenium-catalyzed one-pot synthesis achieves high atom economy and operational simplicity for critical pharmaceutical intermediates with enhanced supply chain reliability.
Patent CN111732541B enables high-purity phenanthridine synthesis with mild conditions and reduced waste, enhancing supply chain reliability for pharmaceutical manufacturing.
Patent CN113636968B enables high-purity API intermediates through ruthenium-catalyzed synthesis with enhanced atom economy and reduced manufacturing costs.
Patent CN109678862A enables room-temperature aqueous synthesis of indole derivatives, reducing manufacturing costs and lead times for pharmaceutical intermediates.
Solve multi-step synthesis challenges for pyrrole intermediates. 50-71% yields, mild conditions, and broad substrate scope. Scale to 100 MT/yr.
Discover how novel biphenyl-type tridentate ligand ruthenium complexes enable ester-to-alcohol hydrogenation at 60-100°C and 3-10MPa, reducing costs and safety risks for pharma production.